Skip to main content
SpringerLink
Log in

Enhanced Glioma Chemosensitivity

  • Chapter
  • First Online:
Tumors of the Central Nervous System, Volume 1

Part of the book series: Tumors of the Central Nervous System ((TCNS,volume 1))

  • 1828 Accesses

Abstract

Currently there is no cure for glioblastoma multiforme (GBM), and with chemotherapy compromised due to resistance, treatment of GBM is often difficult. Survival rates are generally poor, especially in older patients, this emphasizes the need for molecular targets designed to enhance efficiency of chemotherapy while limiting potential side effects. The development of combined therapy that ultimately incorporates molecular inhibition of immortalisation (telomerase), hsp90α, DNA repair (MGMT), EGFR, tumour suppressors, multi-drug resistance and cancer stem cell pathways is paramount to endeavour favourable innovative therapies, which in turn will help reduce the costs and ease the burden on health care.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Cruickshanks N, Shervington L, Patel R, Shervington A (2010) Can hsp90α siRNA combined with TMZ be a future therapy for gliomas? Cancer Invest 28(6):608–614

    Article  PubMed  CAS  Google Scholar 

  • Cui D, Xu Q, Wang K, Che X (2010) Gli1 is a potential target for alleviating multidrug resistance of gliomas. J Neurol Sci 288:156–166

    Article  PubMed  CAS  Google Scholar 

  • Das A, Banik NL, Ray SK (2009) Molecular mechanisms of the combination of retinoid and interferon-gamma for inducing differentiation and increasing apoptosis in human glioblastoma T98G and U87MG cells. Neurochem Res 34:87–101

    Article  PubMed  CAS  Google Scholar 

  • Datta K, Shah P, Srivastava T, Mathur SG, Chattopadhyay P, Sinha S (2004) Sensitizing glioma cells to cisplatin by abrogating the P53 response with antisense oligonucleotides. Cancer Gene Ther 11:525–531

    Article  PubMed  CAS  Google Scholar 

  • Deng Y, Guo X, Ferguson DO, Chang S (2009) Multiple roles for MRE11 at uncapped telomeres. Nature 460:914–918

    Article  PubMed  CAS  Google Scholar 

  • Dinca EB, Lu KV, Sarkaria JN, Pieper RO, Prados MD, Haas-Kogan DA, Vandenberg SR, Berger MS, James CD (2008) P53 small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Cancer Res 68:10034–10039

    Article  PubMed  CAS  Google Scholar 

  • Endoh T, Tsuji N, Asanuma K, Yagihashi A, Watanabe N (2005) Survivin enhances telomerase activity via up-regulation of specificity protein 1- and C-myc-mediated human telomerase reverse transcriptase gene transcription. Exp Cell Res 305:300–311

    Article  PubMed  CAS  Google Scholar 

  • Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C, De MR (2006) Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13:1238–1241

    Article  PubMed  CAS  Google Scholar 

  • Falchetti ML, Fiorenzo P, Mongiardi MP, Petrucci G, Montano N, Maira G, Pierconti F, Larocca LM, Levi A, Pallini R (2006) Telomerase inhibition impairs tumour growth in glioblastoma xenografts. Neurol Res 28:532–537

    Article  PubMed  CAS  Google Scholar 

  • Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, Eberhart CG (2006) Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 66:7445–7452

    Article  PubMed  CAS  Google Scholar 

  • Fukushima T, Takeshima H, Kataoka H (2009) Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res 29:4845–4854

    PubMed  CAS  Google Scholar 

  • Gadji M, Crous AM, Fortin D, Krcek J, Torchia M, Mai S, Drouin R, Klonisch T (2009) EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts. Eur J Pharmacol 625:23–30

    Article  PubMed  CAS  Google Scholar 

  • Gramatzki D, Pantazis G, Schittenhelm J, Tabatabai G, Kohle C, Wick W, Schwarz M, Weller M, Tritschler I (2009) Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/smad pathway in human glioblastoma cells. Oncogene 28:2593–2605

    Article  PubMed  CAS  Google Scholar 

  • Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK, Furnari FB, White FM (2007) Quantitative analysis of egfrviii cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA 104:12867–12872

    Article  PubMed  CAS  Google Scholar 

  • Iwado E, Daido S, Kondo Y, Kondo S (2007) Combined effect of 2-5a-linked antisense against telomerase RNA and conventional therapies on human malignant glioma cells in vitro and in vivo. Int J Oncol 31:1087–1095

    PubMed  CAS  Google Scholar 

  • Jiang H, Alonso MM, Gomez-Manzano C, Piao Y, Fueyo J (2006) Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas. Expert Rev Anticancer Ther 6:1585–1592

    Article  PubMed  CAS  Google Scholar 

  • Krex, D, Klink, B,, Hartmann, C, von DA, Pietsch T, Simon M, Sabel M, Steinbach JP, Heese O, Reifenberger G, Weller M, Schackert G (2007) Long-term survival with glioblastoma multiforme. Brain 130:2596–2606

    Article  PubMed  Google Scholar 

  • Li Y, Zhang T, Schwartz SJ, Sun D (2009) New developments in hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat 12:17–27

    Article  PubMed  CAS  Google Scholar 

  • Marian CO, Cho SK, McEllin BM, Maher EA, Hatanpaa KJ, Madden CJ, Mickey BE, Wright WE, Shay JW, Bachoo RM (2010) The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 16:154–163

    Article  PubMed  CAS  Google Scholar 

  • Ohba S, Hirose Y, Yoshida K, Yazaki T, Kawase T (2010) Inhibition of 90-kd heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells. J Neurosurg 112:33–42

    Article  PubMed  CAS  Google Scholar 

  • Panner A, Murray JC, Berger MS, Pieper RO (2007) Heat shock protein 90alpha recruits FLIPS to the death-inducing signaling complex and contributes to TRAIL resistance in human glioma. Cancer Res 67:9482–9489

    Article  PubMed  CAS  Google Scholar 

  • Patel R, Shervington L, Lea R, Shervington A (2008) Epigenetic silencing of telomerase and a non-alkylating agent as a novel therapeutic approach for glioma. Brain Res 1188:173–181

    Article  PubMed  CAS  Google Scholar 

  • Rittierodt M, Tschernig T, Harada K (2004) Modulation of multidrug-resistance-associated P-glycoprotein in human U-87 MG and HUV-ECC cells with antisense oligodeoxynucleotides to MDR1 mrna. Pathobiology 71:123–128

    Article  PubMed  CAS  Google Scholar 

  • Sauvageot CM, Weatherbee JL, Kesari S, Winters SE, Barnes J, Dellagatta J, Ramakrishna NR, Stiles CD, Kung AL, Kieran MW, Wen PY (2009) Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neurooncol 11:109–121

    CAS  Google Scholar 

  • Sharma VB, Kurian AW, Feldman A, Ford JM (2007) The role of BRCA1 in DNA repair and chemosensitivity. J Clin Oncol 25:18S

    Article  Google Scholar 

  • Shervington A, Patel R (2008) Silencing DNA methyltransferase (DNMT) enhances glioma chemosensitivity. Oligonucleotides 18:365–374

    Article  PubMed  CAS  Google Scholar 

  • Shervington A, Pawar V, Menon S, Thakkar D, Patel R (2009) The sensitization of glioma cells to cisplatin and tamoxifen by the use of catechin. Mol Biol Rep 36:1181–1186

    Article  PubMed  CAS  Google Scholar 

  • Tauchi T, Ohyashiki JH, Ohyashiki K (2007) Telomerase inhibition combined with other chemotherapeutic reagents to enhance anti-cancer effect. Methods Mol Biol 405:181–189

    Article  PubMed  CAS  Google Scholar 

  • Wakabayashi T, Kayama T, Nishikawa R, Takahashi H, Yoshimine T, Hashimoto N, Aoki T, Kurisu K, Natsume A, Ogura M, Yoshida J (2008) A multicenter phase i trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA study). Jpn J Clin Oncol 38:715–718

    Article  PubMed  Google Scholar 

  • Wong VC, Ma J, Hawkins CE (2009) Telomerase inhibition induces acute ATM-dependent growth arrest in human astrocytomas. Cancer Lett 274:151–159

    Article  PubMed  CAS  Google Scholar 

  • Xu GW, Mymryk JS, Cairncross JG (2005) Inactivation of P53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cisplatin. J Neurooncol 74:141–149

    Article  PubMed  CAS  Google Scholar 

  • Yacoub A, Park MA, Gupta P, Rahmani M, Zhang G, Hamed H, Hanna D, Sarkar D, Lebedeva IV, Emdad L, Sauane M, Vozhilla N, Spiegel S, Koumenis C, Graf M, Curiel DT, Grant S, Fisher PB, Dent P (2008) Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Mol Cancer Ther 7:297–313

    Article  PubMed  CAS  Google Scholar 

  • Yang SH, Kim YH, Kim JW, Park CK, Park SH, Jung HW (2009) Methylation status of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene promoter in world health organization grade III gliomas. J Korean Neurosurg Soc 46:385–388

    Article  PubMed  CAS  Google Scholar 

  • Zhao P, Wang C, Fu Z, You Y, Cheng Y, Lu X, Lu A, Liu N, Pu P, Kang C, Salford LG, Fan X (2007) Lentiviral vector mediated sirna knock-down of htert results in diminished capacity in invasiveness and in vivo growth of human glioma cells in a telomere length-independent manner. Int J Oncol 31:361–368

    PubMed  CAS  Google Scholar 

  • Zhu CJ, Li YB, Wong MC (2003) Expression of antisense bcl-2 cdna abolishes tumorigenicity and enhances chemosensitivity of human malignant glioma cells. J Neurosci Res 74:60–66

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Brain Tumour North West, Faculty of Science, University of Central Lancashire, Preston, UK

    Rahima Patel, Leroy Shervington & Amal Shervington

Authors
  1. Rahima Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leroy Shervington
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amal Shervington
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amal Shervington .

Editor information

Editors and Affiliations

  1. Dept. Biological Sciences, Kean University, 1000 Moris Avenue, Union, 07083, New Jersey, USA

    M. A. Hayat

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Patel, R., Shervington, L., Shervington, A. (2011). Enhanced Glioma Chemosensitivity. In: Hayat, M. (eds) Tumors of the Central Nervous System, Volume 1. Tumors of the Central Nervous System, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-0344-5_28

Download citation

  • DOI: https://doi.org/10.1007/978-94-007-0344-5_28

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-007-0343-8

  • Online ISBN: 978-94-007-0344-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation